Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amoxicillin/omeprazole/rifabutin - RedHill Biopharma

Next Previous
Drug Profile

Amoxicillin/omeprazole/rifabutin - RedHill Biopharma

Alternative Names: Amoxicillin/Omeprazole magnesium/Rifabutin; Amoxicillin/omeprazole/rifabutin; Amoxicillin/pantoprazole/rifabutin; Amoxicillin/rifabutin/omeprazole; Heliconda; Omeprazole/amoxicillin/rifabutin; RHB-105; Rifabutin/amoxicillin/omeprazole; TALICIA

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antibacterials; Antituberculars; Antiulcers; Aza compounds; Benzimidazoles; Ethers; Gastric antisecretories; Penicillins; Piperidines; Rifamycins; Small molecules; Spiro compounds
  • Mechanism of Action Cell wall inhibitors; DNA-directed RNA polymerase inhibitors; Penicillin-binding protein inhibitors; Protein 50S ribosomal subunit inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Helicobacter infections

Most Recent Events

  • 18 Mar 2025 RedHill Biopharma announces intention to submit MAA to Medicines and Healthcare products Regulatory Agency for Helicobacter infections in 2025
  • 18 Mar 2025 RedHill Biopharma anticipates approval for Amoxicillin/omeprazole/rifabutin for Helicobacter infections in fourth quarter of 2025
  • 21 Aug 2024 Launched for Helicobacter infections (Treatment-naive) in United Arab Emirates (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top